EFR_Article_Royalty_Tags_BiosciBD.xls
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAGAHAI
1
RoyaltyOther Sales CompensationDeal DateR&DClientEFR$200M (%)EFR$500M (%)EFR$1B (%)Deal Size ($M)Maximum Share (%)Deal SubjectExclusivityDeal TypeStageDiseaseIndicationTechnologySub-TechnologyUpfront Cash ($M)Upfront Equity ($M)Contingent Equity ($M)R&D Support ($M)FTE Rate ($M)Loan ($M)Dev / Reg Milestones ($M)Other Milestones ($M)Total Precommercial Payments ($M)Sales Milestones ($M)Marketing Fee (%)Transfer Price (%)Manufacture Cost + (%)Profit Split (%)Licensor CategoryLicensee CategoryTerritory
2
Tag11/2016TetraLogic PharmaceuticalsMedivir 5.00 5.00 6.25 165.00 10.00 Remetinostat for lymphoma and birinapant for solid tumorsExclusiveAsset PurchasePhase IICancerLymphoma, Solid TumorsDrug Delivery, SyntheticsSmall Molecule 12.00 7.00 25.00 44.00 121.00 2013-15 IPOsWorldwide
3
Tag9/2016ViventiaEleven Biotherapeutics 2.00 2.00 2.00 36.00 2.00 Acquisition for sharesExclusiveAcquisition, EquityPhase IIICancerBroad Focus CancerMonoclonals, Recombinant DNAConjugates 13.50 22.50 36.00 2013-15 IPOsWorldwide
4
Tag6/2016Eleven BiotherapeuticsRoche 7.50 7.50 7.50 270.00
EBI-031 (IL-6 antagonist antibody) for diabetic macular edema and uveitis
ExclusiveLicense, OptionPreclinicalOphthalmicBroad Focus OphthalmicMonoclonalsHumanized Abs 7.50 197.50 65.00 270.00 2013-15 IPOsTop PharmaWorldwide
5
Tag6/2016
Taxus Cardium Pharmaceuticals, Angionetics
Huapont Life Sciences 5.75 7.30 8.65 3.00 10.00 Generx (Ad5FGF-4) for cardio in mainland ChinaExclusiveDistribution, EquityPhase IIICardiovascularAngina, Myocardial InfarctionOligonucleotidesGene Therapy 1.00 2.00 3.00 20.00 Asia
6
Tag5/2016Immune PharmaceuticalsNovel Pain Therapeutics 7.50 8.75 9.38 161.00 10.00 AmiKet and AmiKet Nano for peripheral neuropathic painExclusiveDevelopment, Equity, License, OptionPhase II, FormulationCentral Nervous SystemPainDrug Delivery, SyntheticsSmall Molecule, Topical 15.00 1.00 25.00 41.00 120.00 Worldwide
7
Tag5/2016Nektar TherapeuticsDaiichi Sankyo 20.00 20.00 20.00 80.00 20.00
Onzeald (etirinotecan pegol Topo-1 inhib) for breast and brain cancer in Europe & Turkey
ExclusiveCo-Development, License, SupplyPhase IIICancerBrain, BreastDrug Delivery, SyntheticsPEG Products 20.00 35.00 55.00 25.00 Japanese PharmaEurope, Middle East
8
Tag1/2016
Hebrew University, Yissum Research Development
Immune Pharmaceuticals 5.00 5.00 5.00 5.33 5.00
Topical delivery of Cyclosporine A by means of biodegradable
nanoparticles
ExclusiveDevelopment, Equity, License, ResearchPreclinicalDrug Delivery, SyntheticsSmall Molecule, Topical 0.53 0.30 3.50 1.00 5.33 Research InstitutionWorldwide
9
Tag7/2015Johns HopkinsProgenics Pharmaceuticals 3.00 3.00 3.00 2.40 3.00
PyL fluorinated PSMA-targeted PET imaging for prostate cancer ex-Oceania
ExclusiveLicenseDiagnosticCancerDiagnosis - Contrast/Imaging, ProstateDiagnostics 0.15 1.25 1.00 2.40 Research Institution
Africa, Asia, Europe, Middle East, NAFTA, South America
10
Tag7/2015LonzaCytoDyn 2.00 2.00 2.00 2.00 Glutamine synthetase expression of PRO 140 monoclonal for HIVNon-exclusiveLicenseDiscoveryInfectious-ViralHuman Immunodeficiency Virus/HIVMonoclonalsWorldwide
11
Tag6/2015
Hebrew University, Yissum Research Development
Immune Pharmaceuticals 3.00 3.00 3.00 4.93 3.00 Topical nano-formulation of AmiKet for painExclusiveLicense, ResearchFormulationCentral Nervous SystemPainDrug Delivery, SyntheticsSmall Molecule, Topical 0.03 0.40 4.50 4.93 Research InstitutionWorldwide
12
Tag6/2015IntrexonOragenics 12.00 12.00 12.00 37.00 12.00 AG013 (oral rinse of Trefoil Factor 1) for chemo-induced mucositisExclusiveDevelopment, Equity, License, LoanPhase IIDental/OralMucositisPeptides 5.00 22.00 10.00 37.00 2013-15 IPOsWorldwide
13
Tag3/2015Oxis International, Oxis BiotechMultiCell Immunotherapeutics 3.00 3.00 3.00 15.88 3.00
Three antibody-drug conjugate products containing OXS-2175 and OXS-4235 for cancer
ExclusiveLicense, ResearchDiscoveryCancerBreast, Multiple MyelomaMonoclonals, SyntheticsConjugates, Small Molecule 0.50 1.13 4.25 10.00 15.88 Worldwide
14
Tag12/2014GlaxoSmithKlineAxovant, Roivant Neurosciences 12.50 12.50 12.50 165.00 12.50
RVT-101 (SB742457 selective 5-HT6 receptor antagonist) for Alzheimer's
ExclusiveAsset PurchasePhase IICentral Nervous SystemAlzheimer's DiseaseSyntheticsSmall Molecule 5.00 75.00 80.00 85.00 Top Pharma2013-15 IPOsWorldwide
15
Tag12/2014Nuo TherapeuticsRohto Pharmaceutical 9.00 9.00 9.00 4.00 9.00 Aurix platelet and plasma therapy system for wound care in JapanExclusiveDistribution, LicenseFiled, DeviceDermatologicWound HealingCell Therapy - Stem Cells/Factors 3.00 1.00 4.00 10.00 Japanese PharmaAsia
16
Tag11/2014Lonza, CutanogenAmarantus Bioscience 2.00 2.00 2.00 9.25 2.00 Option to purchase Engineered Skin Substitute (ESS) for burnsExclusiveAcquisition, Option, SettlementPhase IDermatologicBurns
Cell Therapy - Stem Cells/Factors, Natural Product
0.25 9.00 9.25 Worldwide
17
Tag10/2014Sorrento Therapeutics
Lee’s Pharmaceutical, China Oncology Focus Limited
8.20 9.28 9.64 50.10 10.00 STI-­A1014 (anti­-PD-­L1 human MAb) in ChinaExclusiveEquity, LicensePhase II, Phase ICancerBroad Focus CancerMonoclonalsHuman Abs 1.00 3.60 3.00 0.50 8.10 42.00 Asia
18
Tag9/2014Johns HopkinsSecond Sight 0.25 0.25 0.25 4.04 0.25 Retinal prosthesisNon-exclusiveEquity, License, ResearchDeviceOphthalmicBroad Focus OphthalmicDevice 4.04 Research Institution2013-15 IPOsWorldwide
19
Tag6/2014Dartmouth CollegeCelyad, Celdara Medical 2.00 2.00 2.00 1.63 2.00 Anti-B7-H6 ImmunotherapiesExclusiveDevelopment, LicenseCancer 0.03 1.60 1.63 Research Institution2013-15 IPOsWorldwide
20
Tag6/2014University of IllinoisRespireRx Pharmaceuticals 4.00 4.00 4.00 2.40 4.00
IP related to use of cannabinoids for sleep related breathing disorders
ExclusiveLicenseLead MoleculeCentral Nervous SystemSleep DisordersSyntheticsSmall Molecule 0.48 1.93 2.40 Research InstitutionWorldwide
21
Tag2/2014CelladonServier 3.00 3.00 3.00 107.10 3.00
Option to small molecule SERCA2b modulators for metabolic diseases, including type 2 diabetes, ex-US
ExclusiveLetter of Intent, License, Option, ResearchDiscoveryEndocrinological & Metabolic
Broad Focus Endocrinological & Metabolic, Diabetes
SyntheticsSmall Molecule 2.70 78.40 26.00 107.10 2013-15 IPOsMid Tier Pharma
Africa, Asia, Europe, Middle East, NAFTA, South America
22
Tag1/2014Napo PharmaceuticalsJaguar Animal Health 10.00 10.00 10.00 5.15 10.00 SP-303 (crofelemer) medicinal plant extract for veterinary usageExclusiveLicenseOtherOther/MiscellaneousVeterinaryNatural Product 1.00 2.15 3.15 2.00 Worldwide
23
Tag1/2014PsychoGenicsAmarantus Bioscience 8.00 8.00 8.00 5.25 8.00
Eltoprazine for Levadopa induced dyskinesia associated with Parkinson's ex-Japan, China & Korea
ExclusiveLicensePhase II, Orphan IndicationCentral Nervous SystemParkinson's DiseaseSyntheticsSmall Molecule 0.75 4.50 5.25
Africa, Asia, Europe, Middle East, NAFTA, South America
24
Tag11/2013EgaletShionogi 8.00 10.70 11.60 350.00 12.50 Abuse-deterrent oral hydrocodone opioid productExclusiveDevelopment, Equity, License, TerminationPreclinical, FormulationCentral Nervous SystemPainDrug Delivery, SyntheticsOral, Small Molecule 10.00 15.00 0.25 60.00 80.00 165.00 185.00 2013-15 IPOsJapanese PharmaWorldwide
25
Tag11/2013Endo International, Paladin LabsKnight Therapeutics 22.50 22.50 22.50 9.80 22.50 Spin-out of Impavido (miltefosine) for leishmaniasis ex-USExclusiveAsset Purchase, Equity, LicenseApprovedInfectious-MiscellaneousParasitic-MiscellaneousSyntheticsSmall Molecule
Africa, Asia, Europe, Middle East, NAFTA, South America
26
Tag11/2013PozenHorizon Pharma 10.00 10.00 10.00 10.00
Vimovo (naproxen/esomeprazole magnesium) for arthritis and ankylosing spondylitis in US
ExclusiveLicenseAutoimmune/InflammatoryRheumatoid ArthritisNAFTA
27
Tag10/2013Nerviano Medical SciencesIgnyta 6.50 6.50 6.80 113.00 12.00
Entrectinib (tyrosine kinase Trk inhibitor) plus ROS1 & ALK targets for cancer
ExclusiveDevelopment, License, WarrantPhase I, PreclinicalCancerBroad Focus Cancer, Solid TumorsSyntheticsSmall Molecule 7.00 1.00 55.00 50.00 113.00 2013-15 IPOsWorldwide
28
Tag10/2013VIVUSEndo International, Auxilium 9.50 13.40 15.70 300.00 18.00 Stendra (avanafil) PDE-5 inhibitor for erectile dysfunction in NAExclusive
Co-Development, License, Supply, Termination
ApprovedGenitourinary/GynecologicSexual DysfunctionSyntheticsSmall Molecule 30.00 15.00 45.00 255.00 10.00 NAFTA
29
Tag8/2013Green MolecularChromaDex 4.00 4.00 4.00 0.11 4.00
IP covering topical application of pTeroPure pterostilbene for dermatologic & skin cancer prevention
ExclusiveLicenseFormulationCancer, DermatologicBroad Focus Dermatologic, MelanomaDrug Delivery, Natural ProductTopical 0.03 0.08 0.11 Worldwide
30
Tag8/2013University of New South WalesBenitec 3.00 3.00 3.00 0.83 3.00 Tribetarna program therapy for lung cancerExclusiveLicensePreclinicalCancerLungOligonucleotidesRNAi 0.03 0.80 0.83 Research Institution2013-15 IPOsWorldwide
31
Tag7/2013Array BioPharmaLoxo Oncology 7.00 7.00 7.00 450.25 7.00
Small molecules to p70S6 kinase, telomerase reverse transcriptase, FGF & Trk receptors for cancer
ExclusiveDevelopment, Equity, License, ResearchLead Molecule, DiscoveryCancerBroad Focus CancerSyntheticsSmall Molecule 15.00 72.00 63.25 150.25 300.00 2013-15 IPOsWorldwide
32
Tag7/2013MedistemCytori 3.50 3.50 3.50 0.01 3.50
Stem cell mediated treg activation IP for treatment of autoimmune diseases
ExclusiveLicenseDiscoveryAutoimmune/InflammatoryBroad Focus Autoimmune/InflammatoryCell Therapy - Stem Cells/Factors 0.01 0.01 NAFTA
33
Tag7/2013Nuvo Research
Warner Chilcott, Actavis, Allergan, Galen Limited
10.00 10.00 10.00 14.50 10.00
Synera (topical patch of lidocaine& tetracaine) for dermal pain in US
ExclusiveLicenseApproved, FormulationCentral Nervous SystemPainDrug DeliveryTransdermal 4.50 4.50 10.00 Mid Tier PharmaNAFTA
34
Tag7/2013OptiNose
Otsuka Pharmaceutical, Avanir Pharmaceuticals
11.50 13.00 13.50 110.00 14.00
Intranasal delivery system containing low-dose triptan powder for migraine in NAFTA
ExclusiveCo-Development, LicensePhase III, FormulationCentral Nervous SystemMigraneDrug DeliveryNasal 20.00 40.00 60.00 50.00 Japanese PharmaNAFTA
35
Tag7/2013University Of GuelphStellar Biotechnologies 4.60 4.60 4.60 71.04 4.60
Polysaccharides as immunotherapies and diagnostics for Clostridium difficile infection
ExclusiveDevelopment, Equity, LicensePreclinicalInfectious-BacterialCarbohydrates, Diagnostics 0.25 0.30 6.75 0.07 71.04 63.68 Research InstitutionWorldwide
36
Tag6/2013
Ben Gurion University, B.G. Negev Technologies
Sorrento Therapeutics 1.00 1.00 1.00 1.60 1.00 Development of anti-viral antibodiesExclusiveDevelopment, License, Option, ResearchPhase IInfectious-ViralBroad Focus Infectious-ViralMonoclonalsHumanized Abs 1.60 Research InstitutionWorldwide
37
Tag6/2013ResverlogixRVX Therapeutics 1.00 1.80 3.00 5.00 Compounds for cardio disease excluding Apo A-1ExclusiveLicenseLead MoleculeCardiovascularBroad Focus CardiovascularWorldwide
38
Tag5/2013AradigmGrifols 12.50 15.50 17.75 116.00 20.00
Inhaled ciprofloxacin (Pulmaquin and Lipoquin) for respiratory diseases
ExclusiveCo-Development, Equity, License, OptionPhase II, FormulationRespiratoryBronchitis, Cystic FibrosisDrug Delivery, SyntheticsLiposomes, Small Molecule 26.00 65.00 25.00 116.00 Mid Tier PharmaWorldwide
39
Tag5/2013Eleven BiotherapeuticsThromboGenics 3.00 3.00 3.00 29.20 3.00
Protein therapeutic targeting Slit, Robo or Flrt targets for diabetic macular edema
ExclusiveLicense, ResearchDiscoveryOphthalmicOther OphthalmicPeptides 1.75 2.45 0.35 25.00 29.20 2013-15 IPOsWorldwide
40
Tag5/2013StanfordFate Therapeutics 4.00 4.00 4.00 1.52 4.00 Wnt proteins for stem cell modulationExclusiveDevelopment, Equity, LicenseDiscoveryHematologic, Transplantation
Broad Focus Hematologic, Broad Focus Transplantation
Cell Therapy - Stem Cells/Factors 0.52 1.00 1.52 Research Institution2013-15 IPOsWorldwide
41
Tag4/2013Bind TherapeuticsAstraZeneca 3.50 3.50 4.25 197.00 10.00
AZD2811 (metabolite of the prodrug barasertib) selective inhibitor of Aurora B kinase for cancer
ExclusiveDevelopment, License, OptionPreclinical, FormulationCancerBroad Focus CancerDrug DeliveryOther 4.00 0.33 71.00 97.00 172.00 25.00 2013-15 IPOsTop PharmaWorldwide
42
Tag4/2013Cara TherapeuticsMaruishi Pharmaceutical 13.75 17.50 18.75 43.50 20.00
CR845 (kappa opioid receptor agonist) for pain & uremic pruritus in Japan
ExclusiveEquity, License, SupplyPhase IICentral Nervous System, RenalOther Renal, PainPeptides 15.00 8.00 4.50 6.00 33.50 10.00 10.00 2013-15 IPOsJapanese PharmaAsia
43
Tag4/2013Concert PharmaceuticalsCelgene 5.00 5.00 5.50 355.50 10.00
CDP-730 (PDE4 inhibitor) deuterium-apremilast targeting cancer and inflammation
ExclusiveCo-Development, License, OptionPreclinical
Autoimmune/Inflammatory, Cancer
Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer
SyntheticsSmall Molecule 35.00 133.00 137.50 305.50 50.00 2013-15 IPOsMajor BiotechWorldwide
44
Tag4/2013MedtronicNuVasive 4.00 4.00 4.00 7.50 4.00 Anterior cervical plate products and systemsNon-exclusiveLicense, SettlementDeviceBone DiseaseOther Bone DiseaseDevice 7.50 7.50 Worldwide
45
Tag3/2013Bind TherapeuticsPfizer 2.00 2.00 2.50 403.00 9.00
Accurin nanoparticle-encapsulated MEK and PK1 compounds for cancer
ExclusiveDevelopment, License, OptionPreclinical, FormulationCancerBroad Focus CancerDrug Delivery, SyntheticsOther, Small Molecule 4.00 0.33 99.50 179.50 283.00 120.00 2013-15 IPOsTop PharmaWorldwide
46
Tag3/2013IntrexonAmpliPhi Biosciences 8.00 9.60 9.80 10.50 10.00 Bacteriophage­ therapies for antibiotic resistant infectionsExclusiveEquity, License, Research, TerminationDiscoveryInfectious-BacterialBroad Focus Infectious-BacterialCell Therapy - Stem Cells/Factors 3.00 7.50 10.50 2013-15 IPOsWorldwide
47
Tag3/2013Ligand, CyDexSpectrum Pharmaceuticals 20.00 20.00 20.00 69.00 20.00 Captisol-enabled propylene glycol-free MelphalanExclusiveDevelopment, License
Phase II, Formulation, Orphan Indication
Cancer, TransplantationMultiple Myeloma, Stem Cell/Bone MarrowSyntheticsSmall Molecule 3.00 6.00 9.00 60.00 Worldwide
48
Tag3/2013Washington UniversityChromaDex 4.00 4.00 4.00 0.70 4.00
Nicotinamide Riboside for treatment of neuropathies caused by axon degeneration
ExclusiveDevelopment, LicenseOther/MiscellaneousNutritionals/VitaminsNatural Product 0.14 0.47 0.08 0.70 Research InstitutionWorldwide
49
Tag2/2013Concert PharmaceuticalsJazz Pharmaceuticals 6.00 7.50 9.05 126.10 11.00
JPZ-386 (D-SXB deuterium-modified sodium oxybate) for narcolepsy
ExclusiveDevelopment, LicensePreclinical, Orphan IndicationCentral Nervous SystemSleep DisordersSyntheticsSmall Molecule 4.00 0.32 38.00 12.50 54.50 70.00 2013-15 IPOsWorldwide
50
Tag2/2013ElanBiogen 18.00 18.00 18.00 3,249.00 25.00 Full ownership of Tysabri (natalizumab) for multiple sclerosisExclusiveAsset Purchase, LicenseApproved, Orphan IndicationCentral Nervous SystemMultiple SclerosisMonoclonalsHumanized Abs 3,249.00 Mid Tier PharmaMajor BiotechWorldwide
51
Tag1/2013Bind TherapeuticsAmgen 5.00 5.25 6.38 187.50 11.00
Accurin nanoparticle-encapsulation of AMG-208 kinase inhibitor for solid tumors
ExclusiveDevelopment, License, Option, TerminationPreclinical, FormulationCancerSolid TumorsDrug DeliveryOther 2.00 0.33 116.50 19.00 137.50 50.00 2013-15 IPOsMajor BiotechWorldwide
52
Tag1/2013YaleBind Therapeutics 0.25 0.25 0.25 1.01 0.25
Targeted and high density drug-loaded polymeric materials for treatment of cancer
ExclusiveDevelopment, LicenseDiscoveryCancerBroad Focus CancerSyntheticsSmall Molecule 0.50 0.25 0.26 1.01 Research Institution2013-15 IPOsWorldwide
53
Tag9/2012Ligand, CyDexMEI Pharma 3.00 3.00 3.00 4.70 3.00
Captisol with ME-143 & ME-344 (isoflavone-based drug compounds) for improved solubility
ExclusiveLicense, SupplyLead Molecule, FormulationUnlimitedDrug DeliveryOral 0.08 2.63 2.00 4.71 Worldwide
54
Tag8/2012Bristol-Myers SquibbSynergy Pharmaceuticals 5.00 5.00 5.00 10.40 5.00 FV-100 bicyclic nucleoside analogue for shinglesExclusiveAsset PurchasePhase IIInfectious-ViralOther Infectious-ViralSyntheticsSmall Molecule 1.40 3.00 4.40 6.00 Top PharmaWorldwide
55
Tag8/2012S*BIOMEI Pharma 2.00 2.00 2.00 76.20 2.00
Pracinostat HDAC inhibitor for solid tumors and hematologic disorders
ExclusiveAsset Purchase, EquityPhase IICancer, Hematologic
Leukemia, Lymphoma, Other Hematologic, Solid Tumors
SyntheticsSmall Molecule 0.50 0.50 30.20 15.00 46.20 30.00 Worldwide
56
Tag7/2012Aspen BioCeva Sante Animale 10.00 10.00 10.00 4.80 10.00
Single chain reproductive hormone technology for livestock reproduction
ExclusiveLicenseOtherOther/MiscellaneousVeterinaryRecombinant DNA 0.80 2.00 2.00 4.80 Worldwide
57
Tag7/2012Dartmouth CollegeChromaDex 3.00 3.00 3.00 0.16 3.00 IP covering pharmaceutical use of nicotinamide ribosideExclusiveDevelopment, LicenseOther/MiscellaneousNutritionals/VitaminsNatural Product 0.09 0.03 0.16 0.05 Research InstitutionWorldwide
58
Tag7/2012Juniper PharmaceuticalsScientelle 3.00 3.00 3.00 3.00 Peroxides for bacterial vaginosisExclusiveLicenseLead MoleculeGenitourinary/GynecologicOther Genitourinary/GynecologicWorldwide
59
Tag7/2012Progenics PharmaceuticalsCytoDyn 5.00 5.00 5.00 10.00 5.00 PRO 140 (humanized MAb HIV viral­ entry inhibitor) to treat HIVExclusiveAsset PurchasePhase IIInfectious-ViralHuman Immunodeficiency Virus/HIVMonoclonalsHumanized Abs 3.50 6.50 10.00 Worldwide
60
Tag6/2012Aegis TherapeuticsBiodel 2.38 3.25 4.38 22.12 6.00
ProTek and Intravail technologies for formulations of glucagon to treat diabetes
ExclusiveLicenseFormulationEndocrinological & MetabolicDiabetesDrug DeliveryOther 0.37 5.25 4.00 9.62 12.50 Worldwide
61
Tag6/2012University of California, UC San FranciscouniQure 1.25 1.25 1.25 0.30 1.25 GDNF.AAV2 gene therapy for Parkinson's diseaseNon-exclusiveDevelopment, LicensePreclinical, Orphan IndicationCentral Nervous SystemParkinson's DiseaseOligonucleotidesGene Therapy 0.30 0.30 Research Institution2013-15 IPOsWorldwide
62
Tag5/2012Marina BiotechMonsanto 2.00 2.00 2.00 1.50 2.00 Oligonucleotide delivery systems for siRNA compounds in plantsExclusiveLicense, ResearchOtherOther/MiscellaneousAgricultureOligonucleotidesLigands 1.25 0.25 1.50 Worldwide
63
Tag5/2012Mass General HospitalProQR Therapeutics 2.00 2.00 2.00 0.01 2.00 Novel therapeutics for treatment of cystic fibrosisExclusiveDevelopment, LicensePreclinical, Orphan IndicationRespiratoryCystic Fibrosis 0.01 Research Institution2013-15 IPOsWorldwide
64
Tag5/2012MerckTesaro 10.00 10.60 11.90 181.00 14.00
Niraparib (MK-4827) PARP inhibitor and backup compound, MK-2512 for cancer
ExclusiveCo-Promotion, LicensePhase ICancerBroad Focus CancerSyntheticsSmall Molecule 7.00 57.00 29.50 93.50 87.50 Top PharmaWorldwide
65
Tag4/2012University of TexasMoleculin 3.50 3.80 3.90 1.58 4.00 Novel cancer therapeuticExclusiveDevelopment, LicensePhase ICancerBroad Focus Cancer 0.33 1.25 1.58 Research InstitutionWorldwide
66
Tag3/2012PerkinElmer, Caliper Life SciencesGenMark Diagnostics 3.00 3.30 3.50 4.20 3.50 Diagnostic applications of microfluidic technologyNon-exclusiveLicenseDiagnosticUnlimitedDiagnosticsDNA Probes 0.40 2.00 2.40 1.80 Worldwide
67
Tag3/2012RegeneRx BiopharmaceuticalsLee’s Pharmaceutical 6.55 6.22 6.00 4.00 10.00
Thymosin Beta 4-based products for ophthalmic and cardio diseases in China
ExclusiveLetter of Intent, LicensePhase IICardiovascular, Ophthalmic
Broad Focus Cardiovascular, Broad Focus Ophthalmic
Peptides 0.40 0.50 0.90 3.10 Asia
68
Tag3/2012University of PittsburghStemline Therapeutics 5.00 5.00 5.00 0.33 5.00 IND data for dendrite and glioma peptide trialNon-exclusiveLicensePreclinical, Orphan IndicationCancerBrain, Other CancerPeptides 0.03 0.30 0.33 Research Institution2013-15 IPOsWorldwide
69
Tag3/2012YaleMedistem 2.00 2.00 2.00 1.15 2.00 Endometrial derived stem cells to treat diabetesExclusiveDevelopment, LicensePreclinicalEndocrinological & MetabolicDiabetesCell Therapy - Stem Cells/Factors 0.05 1.10 1.15 Research InstitutionWorldwide
70
Tag2/2012Concert Pharmaceuticals
Otsuka Pharmaceutical, Avanir Pharmaceuticals
6.00 6.40 7.20 256.00 10.00
AVP-786 (deuterium-modified dextromethorphan) for neurological and psychiatric disorders
ExclusiveDevelopment, LicensePreclinical
Central Nervous System, Psychiatric
Broad Focus Central Nervous System, Broad Focus Psychiatric
SyntheticsSmall Molecule 2.00 0.30 56.00 73.00 131.00 125.00 2013-15 IPOsJapanese PharmaWorldwide
71
Tag2/2012Sheba Medical CenterOrgenesis 3.50 3.50 3.50 3.08 3.50
Methods of inducing regulated pancreatic hormone production in islet cells for diabetes
ExclusiveLicenseDiscoveryEndocrinological & MetabolicDiabetesCell Therapy - Stem Cells/Factors 0.08 1.00 1.08 2.00 Research InstitutionWorldwide
72
Tag1/2012Health DiscoveryNeoGenomics 6.50 6.50 6.50 8.00 6.50 genomic biomarkers for prostate & other cancersExclusiveEquity, LicenseDiagnostic, ReagentCancerBroad Focus Cancer, ProstateDiagnostics 1.00 2.00 3.00 5.00 Worldwide
73
Tag1/2012NIHKineMed 3.87 3.95 4.48 18.04 5.00 5a peptide for cardio vascular diseasesExclusiveLicensePreclinicalCardiovascular
Angina, Atherosclerosis/Coronary Artery Disease, Congestive Heart Failure, Myocardial Infarction, Other Cardiovascular, Peripheral Arterial Disease
Peptides 0.29 3.75 11.04 7.00 Research InstitutionWorldwide
74
Tag1/2012UluruMelmed Holdings 10.00 10.00 10.00 0.25 40.00
Altrazeal wound healing device in Europe, Mideast, Africa and Oceania
ExclusiveLicense, SupplyDeviceDermatologicWound HealingDevice 0.25 0.25 30.00 Africa, Asia, Europe, Middle East
75
Tag12/2011Texas A&MOragenics 5.00 5.00 5.00 0.71 5.00 Site directed mutagenesis of Mutacin 1140ExclusiveDevelopment, LicensePreclinicalPeptides 0.01 0.70 0.71 Research InstitutionWorldwide
76
Tag11/2011IntrexonLilly, Elanco 10.50 11.40 11.70 3.40 12.00
Novel canine IL-12, IL-1ra & Insulin, feline Insulin & equine IL-1ra compounds
ExclusiveLicense, ResearchDiscoveryOther/MiscellaneousVeterinaryRecombinant DNA 0.15 1.00 2.25 3.40 2013-15 IPOsTop PharmaWorldwide
77
Tag11/2011Leukemia & Lymphoma SocietyCuris 5.00 5.00 5.00 1.50 5.00
Oral small molecule dual Pi3K and HDAC inhibitor CUDC-907 for B-cell lymphoma and multiple myeloma
ExclusiveDevelopment, License, ResearchPreclinical, Orphan IndicationCancerLymphoma, Multiple MyelomaDrug Delivery, SyntheticsOral, Small Molecule 4.00 1.50 1.50 Research InstitutionWorldwide
78
Tag10/2011GlycoMimeticsPfizer 10.00 10.00 10.90 332.50 13.00
GMI-1070 pan-selectin antagonist for vaso-occlusive crisis associated with sickle cell disease
ExclusiveCo-Development, License, LoanPhase II, Orphan IndicationHematologicSickle Cell DiseaseSyntheticsSmall Molecule 22.50 110.00 65.00 197.50 135.00 2013-15 IPOsTop PharmaWorldwide
79
Tag10/2011Rosetta GenomicsAvatao Biotech 3.00 3.00 3.00 8.30 3.00 miRview microRNA metastatic cancer diagnostic tests in ChinaExclusiveLicenseDiagnosticCancerBroad Focus CancerDiagnosticsDNA Probes 0.60 0.20 0.80 7.50 Asia
80
Tag9/2011Children’s Cancer Institute AustraliaCleveland BioLabs, Panacela Labs 2.00 2.00 2.00 6.50 2.00
Small Molecules Inhibiting Oncoprotein MYC for solid tumor treatment
ExclusiveEquity, License, OptionPreclinicalCancerSolid TumorsSyntheticsSmall Molecule 6.50 6.50 Research InstitutionWorldwide
81
Tag9/2011Concert PharmaceuticalsTeva, Auspex Pharmaceuticals 2.50 2.50 2.50 2.50 Patent assignment related to deuterated pirfenidoneExclusiveAssignment, LicensePreclinicalRespiratoryOther RespiratorySyntheticsSmall Molecule2013-15 IPOs
Mid Tier Pharma, 2013-15 IPOs
Worldwide
82
Tag9/2011NumabSucampo Pharmaceuticals 3.00 3.00 4.00 86.40 7.00 High affinity antibodies to IL5-R/CD3 and three additional targetsExclusiveCo-Development, License, LoanDiscoveryUnlimitedMonoclonals 0.44 6.30 38.80 41.30 86.40 Worldwide
83
Tag9/2011Opko HealthNikon, Optos 5.00 5.00 5.00 17.50 5.00 Spectral OCT SLO etinal scanning deviceExclusiveAsset PurchaseDeviceOphthalmicOther OphthalmicDevice 17.50 17.50 Worldwide
84
Tag9/2011Rockefeller UniversityContraFect 5.00 5.00 5.00 5.56 5.00 CF-301 staphylococcal-specific lysin proteinExclusiveDevelopment, LicensePreclinicalInfectious-BacterialOther Infectious-BacterialRecombinant DNA 0.56 5.00 5.56 Research Institution2013-15 IPOsWorldwide
85
Tag9/2011University of Central FloridaRed Hill Biopharma 7.00 7.00 7.00 0.05 7.00
Protocol for detection of Mycobacterium avium subspecies paratuberculosis in blood
ExclusiveDevelopment, LicenseGastrointestinal
IBD - Crohn's Disease, IBD - Other, IBD - Ulcerative Colitis
Diagnostics 0.05 Research InstitutionWorldwide
86
Tag7/2011Cubist, Merck, Trius TherapeuticsBayer 17.00 17.00 17.00 94.10 17.00
Tedizolid phosphate antibiotic (TR-701) in Asia-Pacific, Africa, Latin America and the Middle East
ExclusiveCo-Development, LicensePhase IIIInfectious-Bacterial
Broad Focus Infectious-Bacterial, Pneumonia
SyntheticsSmall Molecule 25.00 0.37 34.10 59.10 35.00 Top PharmaTop PharmaAfrica, Asia, Middle East, South America
87
Tag7/2011DurectZogenix 5.00 6.20 8.35 105.25 12.00
Relday (SR delivery of risperidone) for schizophrenia and bipolar disorder
ExclusiveDevelopment, License, Option, SupplyPreclinical, FormulationPsychiatricBipolar Disorder, SchizophreniaDrug DeliverySustained Release 2.25 38.00 40.25 65.00 Worldwide
88
Tag6/2011Halozyme TherapeuticsIntrexon 7.00 9.00 10.00 77.00 11.00
Subcutaneous formulation of recombinant human alpha-1 anti-trypsin for genetic emphysema
ExclusiveDevelopment, License, Supply, Termination
Preclinical, Formulation, Orphan Indication
Other/Miscellaneous, Respiratory
Genetic Disorders, Other RespiratoryHyaluronic acid, Recombinant DNA 13.00 44.00 10.00 67.00 10.00 20.00 2013-15 IPOsWorldwide
89
Tag6/2011Scolr PharmaSyntrix 4.00 4.00 4.00 0.02 4.00 O-desmethyltramadol opioid for treatment of painExclusiveLicenseCentral Nervous SystemPainSyntheticsSmall Molecule 0.02 0.02 Worldwide
90
Tag5/2011Halozyme TherapeuticsShire, ViroPharma 10.00 10.00 10.00 83.00 10.00
CINRYZE with rHuPH20 (hyaluronidase) subcutaneous delivery for hereditary angioedema
ExclusiveDevelopment, License, Supply
Preclinical, Formulation, Orphan Indication
Autoimmune/Inflammatory, Other/Miscellaneous
Genetic Disorders, Other Autoimmune/Inflammatory
Drug Delivery, Recombinant DNATransdermal 9.00 44.00 30.00 83.00 Major BiotechWorldwide
91
Tag5/2011Oasmia PharmaceuticalMedison Pharma 30.00 30.00 30.00 0.56 30.00 Paclical for ovarian and lung cancer in Israel and TurkeyExclusiveLicense, SupplyPhase IIICancerLung, OvarianNatural Product 0.28 0.28 0.56 2013-15 IPOsMiddle East
92
Tag4/2011
Hebrew University, Yissum Research Development
Immune Pharmaceuticals 4.50 4.50 4.50 15.48 4.50
Antibody nanoparticle conjugates for the targeted delivery
of active agents conjugated to antibodie
ExclusiveDevelopment, License, ResearchPreclinicalDrug Delivery, MonoclonalsHuman Abs 0.03 1.50 8.55 5.40 15.48 Research InstitutionWorldwide
93
Tag4/2011
University of California, UC San Diego, Dana-Farber
Adamis Pharmaceuticals 2.00 2.00 2.00 1.92 2.00
Telomerase reverse transcription antigen for cancer immunization in US
ExclusiveDevelopment, LicensePhase ICancerBroad Focus CancerVaccines 0.06 0.98 0.88 1.92 Research InstitutionNAFTA
94
Tag3/2011Cornell UniversityStrongbridge Biopharma 2.50 2.50 2.50 3.01 2.50 Commensal bacteria as signal mediatorsExclusiveDevelopment, LicensePreclinical 0.44 2.33 0.25 3.01 Research Institution2013-15 IPOsWorldwide
95
Tag2/2011Marina BiotechDebio Group, Debiopharm 10.00 10.00 11.00 25.60 14.00 RNAi therapeutics to HRAS & FGFR3 for bladder cancerExclusiveLicense, Research, TerminationDiscovery, Orphan IndicationCancerBladderOligonucleotidesRNAi 1.60 24.00 25.60 Worldwide
96
Tag2/2011Progenics Pharmaceuticals
Valeant Pharmaceuticals, Salix Pharmaceuticals
16.00 16.60 17.80 350.00 19.00 Relistor (methylnaltrexone) for constipation ex-JapanExclusiveLicenseApprovedGastrointestinalBowel Movement DisordersSyntheticsSmall Molecule 60.00 0.36 40.00 50.00 150.00 200.00 Mid Tier Pharma
Africa, Asia, Europe, Middle East, NAFTA, South America
97
Tag2/2011University of MiamiHeat Biologics 5.00 5.00 5.00 0.05 5.00 HIV/SIV Vaccine technologyExclusiveLicenseInfectious-ViralHuman Immunodeficiency Virus/HIVVaccines 0.05 Research Institution2013-15 IPOsWorldwide
98
Tag2/2011University of MiamiHeat Biologics 5.00 5.00 5.00 5.00 Heat Shock Protein GP96 VaccinationExclusiveLicenseVaccinesResearch Institution2013-15 IPOsWorldwide
99
Tag2/2011University of MiamiHeat Biologics 5.00 5.00 5.00 0.01 5.00 Vaccine for treatment of non small cell lung cancerExclusiveLicenseCancerLungVaccines 0.01 Research Institution2013-15 IPOsWorldwide
100
Tag2/2011University of MiamiHeat Biologics 5.00 5.00 5.00 Allogeneic Cancer Cell-based immunotherapyExclusiveLicenseDiscoveryCancerBroad Focus CancerCell Therapy - Stem Cells/FactorsResearch Institution2013-15 IPOsWorldwide
Loading...
Main menu